Patients with ulcerative colitis will get treatment with Takeda’s biologic Entyvio on the National Health Service in England and Wales, after cost regulators issued final guidance on its use.

According to National Institute for Health and Care Excellence guidelines, Enyvio (vedolizumab) should be considered for adults with moderate-to-severe UC when conventional therapy or TNF-alpha inhibitors doesn’t work or can’t be tolerated.  

The NHS list price for Entyvio is £2,050 per 300mg vial, but NICE’s endorsement is dependent a confidential patient access scheme offering the drug at a reduced rate to help secure its cost effectiveness.

More than 140,000 people in the UK suffer from UC, a chronic and relapsing condition which is characterised by unpredictable symptoms such as urgent diarrhoea, rectal bleeding and extreme fatigue, and thus can significantly affect quality of life.

Enytvio is a novel alpha-4 beta-7 integrin antagonist which works by blocking a key inflammatory marker on white blood cells. Many experts consider the drug a step-change in the management of the disease, because it is the first to suppresses immune activity only in the gut as opposed across the whole body.